Compare SBLX & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBLX | PFSA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.7M |
| IPO Year | N/A | N/A |
| Metric | SBLX | PFSA |
|---|---|---|
| Price | $2.35 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.8K | ★ 2.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $0.05 |
| 52 Week High | $7.85 | $4.22 |
| Indicator | SBLX | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 60.01 |
| Support Level | $2.25 | $1.50 |
| Resistance Level | $2.82 | $4.22 |
| Average True Range (ATR) | 0.26 | 0.29 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 23.92 | 39.59 |
StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.